Genesis Reference Laboratories, LLC

Genesis Reference Laboratories, LLC was paid $37.01M by Medicaid between Jan 2019 and Dec 2024, across 90 billing codes. Its largest line is G0483, Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed — 51% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Florida

Rank by total paid#6 of 225

Median peer was paid$74K

This provider vs. median503×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2019	182,672	$2.72M
2020	204,320	$5.36M
2021	305,601	$6.35M
2022	180,662	$5.27M
2023	137,990	$7.99M
2024incomplete	170,125	$9.33M

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
G0483	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed	51%	120,995	45,980	$18.92M
U0004	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r	21%	161,010	77,561	$7.72M
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.7%	31,305	12,027	$999K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	2.5%	84,882	42,971	$907K
87633	Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets	2.1%	7,343	5,968	$771K
G0482	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed	1.1%	14,264	7,089	$418K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	1.0%	15,810	10,681	$383K
80323		<1%	25,246	15,953	$261K
80346		<1%	27,387	17,774	$228K
80361		<1%	27,360	17,820	$227K
80354		<1%	27,662	17,981	$225K
80358		<1%	27,056	17,571	$222K

78 more codes

80348		<1%	27,251	$221K
80338		<1%	23,446	$221K
80365		<1%	26,746	$218K
80321		<1%	21,907	$214K
80359		<1%	25,620	$214K
80345		<1%	23,724	$212K
80357		<1%	21,063	$210K
80360		<1%	24,269	$210K
80364		<1%	22,255	$207K
80351		<1%	22,284	$206K
80371		<1%	20,774	$206K
80373		<1%	26,001	$199K
80367		<1%	20,654	$196K
80372		<1%	25,667	$196K
80355		<1%	23,158	$193K
80368		<1%	21,861	$193K
80336		<1%	20,632	$191K
80339		<1%	17,084	$190K
80333		<1%	20,238	$189K
80342		<1%	15,670	$180K
80366		<1%	18,238	$178K
80370		<1%	18,443	$174K
87640		<1%	11,266	$137K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	<1%	3,462	$123K
87637	Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV	<1%	1,596	$108K
87486		<1%	8,333	$86K
G2024	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source	<1%	6,516	$85K
87581		<1%	7,602	$82K
U0002	2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc	<1%	1,641	$58K
87636	Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B	<1%	531	$54K
87481		<1%	3,457	$53K
80349		<1%	8,429	$53K
87653		<1%	4,700	$46K
87511		<1%	2,695	$37K
80332		<1%	5,813	$36K
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	2,030	$36K
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	2,024	$35K
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	2,044	$35K
87631		<1%	769	$34K
80369		<1%	4,023	$22K
87150		<1%	1,979	$21K
80324		<1%	3,479	$19K
87563		<1%	1,076	$16K
G0481	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed	<1%	1,817	$15K
87541		<1%	1,175	$10K
87507		<1%	136	$10K
80363		<1%	3,788	$9K
80375		<1%	2,514	$9K
87529		<1%	244	$7K
80344		<1%	3,497	$7K
87632		<1%	318	$7K
83992		<1%	4,756	$7K
80350		<1%	1,116	$7K
80353		<1%	5,198	$6K
80362		<1%	906	$6K
80325		<1%	3,497	$6K
80356		<1%	5,016	$5K
80335		<1%	447	$5K
80329		<1%	477	$4K
80376		<1%	2,754	$4K
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	229	$3K
80374		<1%	1,438	$2K
87500		<1%	229	$2K
87641		<1%	146	$1K
80334		<1%	214	$968.29
87624	Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types	<1%	186	$665.92
87635	Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe	<1%	12	$526.68
87186		<1%	48	$325.26
87088		<1%	48	$296.94
80347		<1%	199	$291.65
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	47	$279.91
87086	Culture, bacterial; quantitative colony count, urine	<1%	32	$152.68
81025		<1%	12	$86.10
86663		<1%	20	$81.60
87506		<1%	12	$57.48
86658		<1%	20	$54.88
80343		<1%	38	$51.12
80337		0%	14	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialFREITAS, PHILIP (MANAGING MEMBER)

Same official

Other billing entities under FREITAS, PHILIP

Full network →

Provider	Location	Paid
Genesis Reference Laboratories, LLC	Centennial, CO	$933K

Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.